You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed Leukemia

Showing 1 - 25 of 9,565
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Refractory Leukemia, Relapsed Leukemia, Acute Myelogenous Leukemia Trial in Miami (STING-Dependent Activators (STAVs) Loaded

Not yet recruiting
  • Refractory Leukemia
  • +4 more
  • STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells
  • Dendritic Cell Vaccine
  • Miami, Florida
    University of Miami
Jan 23, 2023

Relapsed Adult ALL, Relapsed Adult AML Trial in Changchun (Plerixafor)

Active, not recruiting
  • Relapsed Adult ALL
  • Relapsed Adult AML
  • Changchun, Jilin, China
    First Hospital of Jilin University
Nov 19, 2023

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • anti Tim-3/CD123 CAR-T cell therapy
  • Xuzhou, Jiangsu, China
    Kailin Xu
Nov 4, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in São Paulo (Bortezomib)

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • Acute Lymphoblastic Leukemia With Failed Remission
  • São Paulo, SP, Brazil
    Instituto do Cancer do Estado de Sao Paulo
Sep 12, 2023

Relapsed/Refractory Chronic Lymphocytic Leukemia Trial in Tianjin (GNC-035)

Not yet recruiting
  • Relapsed/Refractory Chronic Lymphocytic Leukemia
  • Tianjin, Tianjin, China
    Institute of Hematology and Blood Diseases Hospital, Chinese Aca
Jul 13, 2023

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

Acute Myeloid Leukemia Trial in Beijing (Ven+CAG)

Recruiting
  • Acute Myeloid Leukemia
  • Beijing, Beijing, China
    Peking University People's Hospital
Jun 23, 2023

Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted

Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • CD123 targeted CAR-NK cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Aug 28, 2023

B-cell Acute Lymphoblastic Leukemia Trial (HY004, Cyclophosphamide, Fludarabine Phosphate)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • HY004
  • +2 more
  • (no location specified)
Aug 18, 2023

B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • (no location specified)
Oct 10, 2023

T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)

Not yet recruiting
  • T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
  • CD7-CART01
  • (no location specified)
Sep 26, 2023

Relapsed/Refractory Acute Myeloid Leukemia Trial in Hangzhou (B7-H3 target, CAR gene modified gdT cell injection)

Recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia
  • B7-H3 target, CAR gene modified gdT cell injection
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital， Zhejiang University School of Med
Feb 15, 2023

Relapsed and/or Refractory Multiple Myeloma, Plasma Cell Leukemia in Relapse Trial in Shanghai (Biological)

Recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Plasma Cell Leukemia in Relapse
  • Biological
  • Shanghai, Shanghai, China
    Shanghai Tongji Hospital
May 29, 2023

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • (no location specified)
Nov 9, 2023

B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia Trial (Blinatumomab)

Not yet recruiting
  • B Precursor Acute Lymphoblastic Leukemia
  • Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
  • (no location specified)
Sep 25, 2023

B-cell Acute Lymphoblastic Leukemia Trial in Hefei (QH103 Cell Injection, Fludarabine, Cyclophosphamide)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • QH103 Cell Injection
  • +2 more
  • Hefei, Anhui, China
    Anhui Provincial Hospital
Sep 21, 2023

Acute Myeloid Leukemia (Relapsed/Refractory) Trial in Suzhou (Selinexor, Chidamide)

Recruiting
  • Acute Myeloid Leukemia (Relapsed/Refractory)
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jul 16, 2023

AML, AML With Mutated NPM1, Hematologic Malignancy Trial (Ziftomenib, Fludarabine, Idarubicin)

Not yet recruiting
  • AML
  • +11 more
  • (no location specified)
Aug 14, 2023

PET-CT Imaging in Relapsed/Refractory Acute Leukemias

Not yet recruiting
  • B Cell
  • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Aug 4, 2023

    Relapsed or Refractory Acute Myeloid Leukemia Trial in Taiyuan (Selinexor, Homoharringtonine, Daunorubicin)

    Recruiting
    • Relapsed or Refractory Acute Myeloid Leukemia
    • Taiyuan, Shanxi, China
      Tao Wang
    Feb 9, 2023

    Relapsed/Refractory Acute Myeloid Leukemia Trial in Hefei (gdT cell injection targeting B7-H3 chimeric antigen receptor)

    Recruiting
    • Relapsed/Refractory Acute Myeloid Leukemia
    • gdT cell injection targeting B7-H3 chimeric antigen receptor
    • Hefei, Anhui, China
      PersonGen Anke Cellular Therapeutice Co., Ltd.
    Jan 31, 2023

    Acute Myeloid Leukemia, High-Risk and Very High-Risk MDS Trial (SGR-2921)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • High-Risk and Very High-Risk Myelodysplastic Syndromes
    • (no location specified)
    Jul 25, 2023

    Relapsed/Refractory Large Granular T Lymphocytic Leukemia Trial in Zhoukou, Tianjin (Linperlisib)

    Not yet recruiting
    • Relapsed/Refractory Large Granular T Lymphocytic Leukemia
    • Zhoukou, Henan, China
    • +1 more
    Dec 22, 2022

    Acute Myeloid Leukemia, MDS Trial in United States (GLB-001)

    Recruiting
    • Acute Myeloid Leukemia
    • Myelodysplastic Syndromes
    • Duarte, California
    • +3 more
    Nov 21, 2023

    Relapsed/Refractory AML Trial in Suzhou (Selinexor, Homoharringtonine, Cytarabine)

    Not yet recruiting
    • Relapsed/Refractory AML
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Mar 28, 2023